Clinical Significance of Anti-Modified Citrullinated Vimentin Antibodies in Palindromic Rheumatism

Objective: This study evaluated anti-modified citrullinated vimentin (anti-MCV) performance in determining the clinical picture and outcomes of palindromic rheumatism (PR). Methods: In a retrospective study, patients with PR with at least 1 year of follow-up diagnosed according to clinical criteria...

Full description

Saved in:
Bibliographic Details
Published in:Laboratory medicine 2021-07, Vol.52 (4), p.357-363
Main Authors: Mahdavi, Aida Malek, Rashtchizadeh, Nadereh, Khaknejad, Mahsanam, Sakhinia, Ebrahim, Khabbazi, Alireza, Kolahi, Sousan
Format: Article
Language:English
Subjects:
Antibodies
Arthritis
Clinical significance
Medical prognosis
Medical research
Medicine, Experimental
Prognosis
Remission (Medicine)
Rheumatism
Rheumatoid factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study evaluated anti-modified citrullinated vimentin (anti-MCV) performance in determining the clinical picture and outcomes of palindromic rheumatism (PR). Methods: In a retrospective study, patients with PR with at least 1 year of follow-up diagnosed according to clinical criteria were enrolled. Anti-MCV antibodies were measured, and levels >20 lU/mL were considered positive. Disease prognosis was assessed according to patients acquiring remission and preventing PR from developing into rheumatoid arthritis (RA) or other diseases. Results: Seventy-six patients with PR with a mean follow-up of 30.57 months (median = 21 months; minimum = 12 months; maximum = 48 months) were included in the study. Anti-MCV antibodies were positive in 69.7% of patients. Metacarpophalangeal (MCP) joint involvement and positive anti-cyclic citrullinated peptides were significantly higher in patients who were anti-MCV-positive, whereas ankle joint involvement was significantly lower. No significant correlation was observed between the anti-MCV titer and the severity of attacks. Remission in patients who were anti-MCV-positive and negative was 75.5% and 78.3%, respectively, with no significant difference. Evolution to RA was observed in only 3.8% of patients who were anti-MCV-positive. No patients who were anti-MCV-negative developed RA. Conclusion: Except for MCP and ankle joint involvement, anti-MCV was not helpful in determining the clinical picture and outcome of PR. Keywords: anti-MCV antibodies, palindromic rheumatism, rheumatoid arthritis, prognosis, response to treatment, remission
ISSN:0007-5027
1943-7730
DOI:10.1093/labmed/lmaa095